Regenyx Medical Ltd. Overview
Regenyx Medical is redefining minimally invasive soft tissue restoration—a cornerstone of plastic and reconstructive surgery. Our lead product, Lipogenyx, is the first fat viability extender: a next-generation fat grafting solution that enhances graft survival and integration, enabling natural-looking, lasting and predictable results in reconstructive and aesthetic procedures. Built on a proprietary synthetic peptide hydrogel technology, Lipogenyx offers a scalable, potentially reimbursable platform that eliminates the need to revision fat grafting procedures and streamlines physicians efficiency and patient satisfaction. Selected for the 2025 MedTech Innovator and ASPS Top 5 Innovation Track, Regenyx is now preparing for its first clinical study and establishing U.S. operations.
Cumulative Funding Raised Over Time ($)
$1.0MFeb 2021
$2.4MJul 2023
$2.4MJun 2025
$3.4MMay 2019
Latest News
growth-positive
Five Plastic Surgery Startups Selected for MTI/ASPS Plastic Surgery Accelerator Competition Finals
MedTech Innovator, in partnership with the American Society of Plastic Surgeons (ASPS), has advanced five startups as finalists in the 2025 MedTech Innovator competition. These startups, which focus on medical device, diagnostic, and digital health technology, will compete for a share of $800,000 in funding awards. The program aims to foster innovation in plastic surgery by providing mentorship and support to early-stage companies. The finalists will be featured at an upcoming event in New Orleans and will receive guidance from ASPS surgeons and industry leaders. MedTech Innovator has a history of supporting over 500 companies, resulting in significant FDA approvals and funding.
Partners
growth-positive
MedTech Innovator Unveils 64 Breakthrough Medtech Startups in its 2025 Cohort - MedTech Innovator
MedTech Innovator (MTI), the worlds largest accelerator for medical technology startups, announced its 2025 Accelerator Cohort, selecting 64 companies from nearly 1,500 global applicants. These companies will participate in a four-month program offering mentorship, strategic guidance, and access to MTIs ecosystem of industry leaders. The cohort includes early and mid-stage medical device, diagnostic, and digital health companies competing for $800,000 in non-dilutive funding. MTIs program aims to de-risk innovation and accelerate U.S. market success. The accelerator includes specialty tracks in partnership with the American Society for Plastic Surgeons and the American Heart Association. MTIs founding sponsors include Johnson & Johnson MedTech and Research Corporation Technologies, with additional support from various industry leaders.
growth-positive
Bone Sci Bio Presents Breakthrough Solutions for Bone Healing
Bone Sci Bio introduces PeptOss, a novel solution for bone treatment that promotes bone regeneration and enables controlled drug delivery. The company will present its product at the MIXiii-BIOMED 2019 Conference and Exhibition. PeptOss has various applications in orthopedic and dental medicine, including treating peri-implantitis and strengthening osteoporotic bones. The technology was patented by BGN Technologies. In pre-clinical trials, PeptOss has shown promising results, outperforming the control by up to 80%. Bone Sci Bio aims to gain FDA approval and address the unmet need in peri-implantitis treatment.
CustomersPartners
growth-positive
Israeli startup seeks to boost bone renewal and allow targeted drug delivery
Israeli startup Bone Sci Bio Ltd. is developing PeptOss, a product that promotes bone formation and repair while enabling controlled drug delivery. The product has applications in orthopedic and dental medicine, including the treatment of peri-implantitis and osteosarcoma. PeptOss is made up of a proprietary peptide that mimics bone proteins and self-assembles as a hydrogel. The technology has shown promising results in pre-clinical trials. The company estimates the bone substitute market to be worth $4.5 billion. Clinical studies and FDA approval are still pending.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.4M |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 4 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | regenyxmed.com/ |
Locations
Prof. A. D. Bergman St 2, Rehovot, Israel
Photos & Videos
2 item(s)
Regenyx Medical Ltd. Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrug DeliveryTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesCore Technology
Materials & SubstancesTags (15)
biopharmaceuticalchronic-patientsdegenerative-diseasestreatmentstissue-regenerationboneorthopedicsosteoporosisregenerative-medicineinflammatory-diseasessustained-releasedrug-deliverypharmaceuticalsdentalpeptidesGeographic Markets
GlobalRegenyx Medical Ltd. Financials
$3.4M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
4
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.0MFeb 2021
$2.4MJul 2023
$2.4MJun 2025
$3.4MMay 2019
Private Equity Funding
Accelerator/Incubator
Jun 2025
Undisclosed
Seed
Jul 2023
$1.4M
Seed
Feb 2021
$1M
Seed
May 2019
$1M
Israel Innovation Authority (Lead), Undisclosed Investor(s) (Lead)
Regenyx Medical Ltd. Lifecycle
Cumulative Funding Raised Over Time
$1.0MFeb 2021
$2.4MJul 2023
$2.4MJun 2025
$3.4MMay 2019
All Events
Accelerator/Incubator
Jun 2025
Undisclosed
Seed
Jul 2023
$1.4M
Seed
Feb 2021
$1M
Seed
May 2019
$1M
Israel Innovation Authority (Lead), Undisclosed Investor(s) (Lead)
Regenyx Medical Ltd. News
4 articles
growth-positive
Five Plastic Surgery Startups Selected for MTI/ASPS Plastic Surgery Accelerator Competition Finals
MedTech Innovator, in partnership with the American Society of Plastic Surgeons (ASPS), has advanced five startups as finalists in the 2025 MedTech Innovator competition. These startups, which focus on medical device, diagnostic, and digital health technology, will compete for a share of $800,000 in funding awards. The program aims to foster innovation in plastic surgery by providing mentorship and support to early-stage companies. The finalists will be featured at an upcoming event in New Orleans and will receive guidance from ASPS surgeons and industry leaders. MedTech Innovator has a history of supporting over 500 companies, resulting in significant FDA approvals and funding.
Partners
growth-positive
MedTech Innovator Unveils 64 Breakthrough Medtech Startups in its 2025 Cohort - MedTech Innovator
MedTech Innovator (MTI), the worlds largest accelerator for medical technology startups, announced its 2025 Accelerator Cohort, selecting 64 companies from nearly 1,500 global applicants. These companies will participate in a four-month program offering mentorship, strategic guidance, and access to MTIs ecosystem of industry leaders. The cohort includes early and mid-stage medical device, diagnostic, and digital health companies competing for $800,000 in non-dilutive funding. MTIs program aims to de-risk innovation and accelerate U.S. market success. The accelerator includes specialty tracks in partnership with the American Society for Plastic Surgeons and the American Heart Association. MTIs founding sponsors include Johnson & Johnson MedTech and Research Corporation Technologies, with additional support from various industry leaders.
growth-positive
Bone Sci Bio Presents Breakthrough Solutions for Bone Healing
Bone Sci Bio introduces PeptOss, a novel solution for bone treatment that promotes bone regeneration and enables controlled drug delivery. The company will present its product at the MIXiii-BIOMED 2019 Conference and Exhibition. PeptOss has various applications in orthopedic and dental medicine, including treating peri-implantitis and strengthening osteoporotic bones. The technology was patented by BGN Technologies. In pre-clinical trials, PeptOss has shown promising results, outperforming the control by up to 80%. Bone Sci Bio aims to gain FDA approval and address the unmet need in peri-implantitis treatment.
CustomersPartners
growth-positive
Israeli startup seeks to boost bone renewal and allow targeted drug delivery
Israeli startup Bone Sci Bio Ltd. is developing PeptOss, a product that promotes bone formation and repair while enabling controlled drug delivery. The product has applications in orthopedic and dental medicine, including the treatment of peri-implantitis and osteosarcoma. PeptOss is made up of a proprietary peptide that mimics bone proteins and self-assembles as a hydrogel. The technology has shown promising results in pre-clinical trials. The company estimates the bone substitute market to be worth $4.5 billion. Clinical studies and FDA approval are still pending.
Customers
Regenyx Medical Ltd. Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Regenyx Medical Ltd. Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Vered Waxman |
| Registrar ID | 515544682 |
| Crunchbase | bone-sci-bio |
| Phone | +972-545223489 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-23T00:00:00.000Z |
| Created | 2019-05-16T00:00:00.000Z |
| Claimed | Yes |